ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

ClinicalTrials.gov ID: NCT03596762

Public ClinicalTrials.gov record NCT03596762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause

Study identification

NCT ID
NCT03596762
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bayer
Industry
Enrollment
199 participants

Conditions and interventions

Interventions

  • Elinzanetant (BAY3427080) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 19, 2018
Primary completion
Nov 20, 2019
Completion
Nov 20, 2019
Last update posted
Mar 9, 2023

2018 – 2019

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Study Site 12 Mesa Arizona 85209
Study Site 19 San Diego California 92108
Study Site 13 Aventura Florida 33180
Study Site 15 Lake Worth Florida 33461
Study Site 18 Atlanta Georgia 30328
Study Site 16 New Orleans Louisiana 70125
Study Site 10 Boston Massachusetts 02114
Study Site 11 Boston Massachusetts 02115
Study Site 17 Las Vegas Nevada 89128
Study Site 14 Houston Texas 77054

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03596762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2023 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03596762 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →